OTC Markets OTCPK - Delayed Quote USD

NanoString Technologies, Inc. (NSTGQ)

0.0926 -0.0074 (-7.40%)
As of 3:20 PM EDT. Market Open.
Loading Chart for NSTGQ
DELL
  • Previous Close 0.1000
  • Open 0.1000
  • Bid --
  • Ask --
  • Day's Range 0.0906 - 0.1140
  • 52 Week Range 0.0400 - 6.6500
  • Volume 353,306
  • Avg. Volume 1,644,775
  • Market Cap (intraday) 4.456M
  • Beta (5Y Monthly) 0.28
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date May 28, 2024 - Jun 1, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 0.25

NanoString Technologies, Inc. develops, manufactures, and sells technology for scientific and clinical information in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter Pro and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, cartridges, ancillary reagents, tips and reagent plates to setup and process samples in instruments; and Prosigna in vitro diagnostic kits. The company is also developing GeoMx DSP system to enable the field of spatial biology. It has collaboration with Lam Research Corporation for the development of NGS sequencing platform and related assays; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer, as well as collaboration with Stanford Medicine, Acrobat Genomics, and Illumina Accelerator to discover new drug targets for gene editing-based therapeutics. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington. On February 4, 2024, NanoString Technologies, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

www.nanostring.com

550

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NSTGQ

Performance Overview: NSTGQ

Trailing total returns as of 5/28/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

NSTGQ
87.65%
S&P 500
11.02%

1-Year Return

NSTGQ
98.40%
S&P 500
25.92%

3-Year Return

NSTGQ
99.83%
S&P 500
26.05%

5-Year Return

NSTGQ
99.67%
S&P 500
87.37%

Compare To: NSTGQ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NSTGQ

Valuation Measures

Annual
As of 5/24/2024
  • Market Cap

    4.81M

  • Enterprise Value

    155.41M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.03

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    0.96

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -102.44%

  • Return on Assets (ttm)

    -30.87%

  • Return on Equity (ttm)

    -1,028.56%

  • Revenue (ttm)

    162.47M

  • Net Income Avi to Common (ttm)

    -166.43M

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    97.1M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -81.48M

Research Analysis: NSTGQ

Company Insights: NSTGQ

Research Reports: NSTGQ

People Also Watch